Breitmeyer James B's Form 4 filing
Oncternal Therapeutics, Inc. (ONCT) · filed Apr 17, 2023
- Accession no.
- 0001209191-23-024390
- Filed
- Apr 17, 2023, 6:00 AM ET
- Trade date
- Apr 13-14, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $43.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Breitmeyer James BCIK 0001244823 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 13, 2023 | Common Stock | PPurchaseAcquired | +100,000 | $0.29 | +$29,000 | 146,544 | Indirect | |
| Apr 14, 2023 | Common Stock | PPurchaseAcquired | +47,750 | $0.299 | +$14,277.25 | 194,294 | Indirect | |
| Apr 14, 2023 | Common Stock | PPurchaseAcquired | +2,250 | $0.29 | +$652.5 | 196,544 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.